01862nam 2200421Ia 450 991069913020332120230902162206.0(CKB)5470000002400596(OCoLC)649743183(EXLCZ)99547000000240059620100722d2006 ua 0engurcn|||||||||txtrdacontentcrdamediacrrdacarrierChild access and visitation programs[electronic resource] participant outcomes : program analysis[Washington, D.C.] :Dept. of Health and Human Services, Administration for Children and Families, Office of Child Support Enforcement,[2006]1 online resource (iii, 84 pages)Title from PDF title screen (viewed on July 22, 2010).."Prepared by the Center for Policy Research for the Office of Child Support Enforcement, Administration for Children and Families, Department of Health and Human Services, under contract number 105-00-8300, task order 27, with Policy Studies Inc., January 2006."Includes bibliographical references.Child access and visitation programs Absentee fathersServices forUnited StatesAbsentee mothersServices forUnited StatesVisitation rights (Domestic relations)United StatesAbsentee fathersServices forAbsentee mothersServices forVisitation rights (Domestic relations)United States.Office of Child Support Enforcement.Center for Policy Research (Denver, Colo.)Policy Studies Inc.GPOGPOBOOK9910699130203321Child access and visitation programs3549282UNINA03515nam 2200625 450 991083037180332120230721005314.01-4443-0333-31-4443-0334-1(CKB)1000000000722805(EBL)416357(OCoLC)476247457(SSID)ssj0000104238(PQKBManifestationID)11140788(PQKBTitleCode)TC0000104238(PQKBWorkID)10079636(PQKB)11394892(MiAaPQ)EBC416357(EXLCZ)99100000000072280520160805h20092009 uy 0engur|n|---|||||txtccrAntiplatelet therapy in ischemic heart disease /Stephen D. WiviottHoboken, New Jersey :Wiley-Blackwell,2009.©20091 online resource (311 p.)American Heart Association Clinical SeriesIncludes index.1-4051-7626-1 Contents; Contributors; Preface; Foreword; PART I: Concepts in Platelet Physiology, Function, and Measurement; 1 Platelet physiology and the role of the platelet in ischemic heart disease; 2 Laboratory assessment of platelet function and the effects of antiplatelet agents; PART II: Pharmacology of Oral Antiplatelet Agents; 3 Cyclooxygenase inhibitors; 4 Aspirin response variability and resistance; 5 P2Y[sub(12)] inhibitors: Thienopyridines and direct oral inhibitors; 6 Thienopyridine response variability and resistance; PART III: Pharmacology of Intravenous Antiplatelet Agents7 Pharmacology of intravenous glycoprotein IIb/IIIa antagonists8 Intravenous P2Y[sub(12)] inhibitors; 9 Antiplatelet effects of thrombin inhibitors and fibrinolytic agents; PART IV: Clinical Use of Antiplatelet Agents in Cardiovascular Disease; 10 Antiplatelet therapy in acute coronary syndrome without ST elevation; 11 Antiplatelet therapy in ST-elevation myocardial infarction; 12 Antiplatelet therapy in chronic coronary artery disease; 13 Antiplatelet therapy in peripheral arterial disease; 14 Clinical use of antiplatelet agents in cardiovascular disease: cerebrovascular diseasesPART V: Special Circumstances15 Antiplatelet therapy and coronary bypass surgery: risks and benefits; 16 Management of antiplatelet therapy for non-cardiac surgery; 17 Antiplatelet therapy and coronary stents; Index; A; B; C; D; E; F; G; H; I; J; K; L; M; N; O; P; R; S; T; U; V; W; Author Disclosure Table* Draws from expertise of leaders in antiplatelet therapy* Easy-to-use layout enables rapid browsing* Edited by a member of the prestigious TIMI study group with long-standing experience in the fieldAmerican Heart Association monograph.Coronary heart diseaseChemotherapyBlood plateletsAggregationCoronary heart diseasedrug therapyCoronary heart diseaseChemotherapy.Blood plateletsAggregation.Coronary heart diseasedrug therapy.616.12306616.123061Wiviott Stephen D.1342498Wiviott Stephen D1342498American Heart Association.MiAaPQMiAaPQMiAaPQBOOK9910830371803321Antiplatelet therapy in ischemic heart disease4047776UNINA